Investor's Business Daily on MSN
IBD stock of the day: Ligand Pharma, biotech's royalty arm, breaks out
Ligand Pharmaceuticals is Tuesday's IBD Stock Of The Day. The biotech stock has blown past several buy points on its way to a new breakout.
An age-related blood condition called clonal hematopoiesis was found to worsen gut inflammation and is associated with IBD ...
Finding the right treatment for someone with Crohn’s disease or ulcerative colitis is more of an art than a science. The ...
Spyre Therapeutics CEO Cameron Turtle talks about the search for an IBD treatment on this week's "The Readout LOUD." ...
MedPage Today on MSN
Incidence of Bowel Disease in Kids Nearly Quadrupled Over 40 Years
Danish study also showed more extensive disease at diagnosis, earlier onset with family hi ...
New ECCO dietary therapy guidelines for IBD clarify the role of enteral nutrition, Mediterranean diet, supplements, and RD ...
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive 44 week data from the RELIEVE UCCD study for ...
MedPage Today on MSN
Gastro Practice Settles for Nearly $5M; Acne and JAK Inhibitors; Prior Auth in IBD
News and commentary from the world of gastroenterology and hepatology ...
Severe infections requiring hospitalization are associated with a markedly increased long-term IBD risk, with immune-related ...
Active IBD in older adults is linked to higher odds of cognitive decline over 1 year, and deficits in delayed recall signal an increased risk for active disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results